Carcinoid Syndrome: A Review
Open Access
- 5 March 2020
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 12 (3) , e7186
Abstract
Carcinoid syndrome (CS) is a paraneoplastic syndrome caused by the release of serotonin and other substances from well-differentiated neuroendocrine tumors (NETs). The hallmark symptoms of carcinoid syndrome are flushing and diarrhea; atypical signs and symptoms can include wheezing, abdominal pain, valvular heart disease, telangiectasias, pellagra, and the complications of mesenteric fibrosis, including ureteral obstruction, bowel obstruction, and bowel ischemia. These symptoms are mediated by the release of serotonin (5-HT), histamine, kallikrein, prostaglandins, and tachykinins. The diagnosis of CS requires these symptoms and corresponding elevations in lab tests. Treatment options include surgery and medical management with somatostatin analogs.Keywords
This publication has 45 references indexed in Scilit:
- Neuroendocrine Tumors of the LungCancers, 2012
- Primary bronchial carcinoid: A rare differential diagnosis of pulmonary koch in young adult patientLung India, 2012
- The term "carcinoid" is a misnomer: the evidence based on local invasionJournal of Experimental & Clinical Cancer Research, 2009
- Carcinoid TumorsThe Oncologist, 2008
- Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic TumorsWorld Journal of Surgery, 2008
- Repeat Transarterial Chemoembolization (TACE) for Progressive Hepatic Carcinoid Metastases Provides Results Similar to First TACEJournal of Gastrointestinal Surgery, 2007
- Pharmacology of serotonin: what a clinician should knowGut, 2004
- Carcinoid heart disease: presentation, diagnosis, and managementHeart, 2004
- Somatostatin Receptor Scintigraphy in Patients with Carcinoid TumorsWorld Journal of Surgery, 1996
- Treatment of Carcinoid Syndrome with Recombinant Interferon Alpha-2aActa Oncologica, 1993